CRISPR Therapeutics (NASDAQ:CRSP) Releases Earnings Results, Misses Expectations By $0.09 EPS

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings data on Monday. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.09), FiscalAI reports. CRISPR Therapeutics had a negative return on equity of 24.96% and a negative net margin of 1,812.07%. The business had revenue of $12.67 million during the quarter, compared to the consensus estimate of $14.75 million. The firm’s revenue was up 1311.1% on a year-over-year basis.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $49.99 on Wednesday. The firm has a fifty day moving average price of $53.86 and a two-hundred day moving average price of $52.85. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. CRISPR Therapeutics has a one year low of $44.12 and a one year high of $63.45. The company has a market cap of $4.83 billion, a price-to-earnings ratio of -10.55 and a beta of 1.92.

Insider Activity

In related news, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the completion of the sale, the director owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. This trade represents a 45.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 47,837 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 93,558 shares of company stock worth $4,881,663. Company insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CRSP shares. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Tuesday. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY generated $99 million in third-quarter revenue, up 30% from the prior quarter and nearly sixfold year over year. The therapy also gained pediatric approvals in the U.K., the UAE and Bahrain, expanding its potential reach. Company business update and results
• Positive Sentiment: The FDA granted CTX310 regenerative medicine designations, and the company flagged upcoming clinical data presentations for CTX310 and zugo-cel. These developments may provide pipeline catalysts, although they do not guarantee success. Company pipeline update
• Positive Sentiment: Needham reaffirmed its Buy rating and $82 price target, signaling analyst confidence in potential upside. Needham rating
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His manufacturing and technical-operations experience could help support development and commercialization, but the appointment’s financial impact is not yet clear. CTO appointment
• Negative Sentiment: CRSP reported a third-quarter loss of $1.15 per share, wider than the $1.06 consensus loss. Reported revenue of $12.67 million also fell short of the roughly $14.75 million estimate, despite strong year-over-year growth—an earnings miss that may pressure the shares. Quarterly results coverage

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.